The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

Summary The Myeloma X trial ( ISCRTN 60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation ( ASCT ) or weekly cyclophosphamide following re‐induction therapy. Cytogenetic analysis performed at trial registration defined t(4;14), t(14;16) and del(17p) as high‐risk. The effect of cytogenetics on time to progression ( TTP ) and overall survival was...